It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
P-glycoprotein (P-gp) largely influences the pharmacokinetics (PK) and toxicities of xenobiotics in a patient-specific manner so that personalized drug scheduling may lead to significant patient’s benefit. This systems pharmacology study investigated P-gp activity in mice according to organ, sex, feeding status, and circadian time. Sex-specific circadian changes were found in P-gp ileum mRNA and protein levels, circadian amplitudes being larger in females as compared to males. Plasma, ileum and liver concentrations of talinolol, a pure P-gp substrate, significantly differed according to sex, feeding and circadian timing. A physiologically-based PK model was designed to recapitulate these datasets. Estimated mesors (rhythm-adjusted mean) of ileum and hepatic P-gp activity were higher in males as compared to females. Circadian amplitudes were consistently higher in females and circadian maxima varied by up to 10 h with respect to sex. Fasting increased P-gp activity mesor and dampened its rhythm. Ex-vivo bioluminescence recordings of ileum mucosae from transgenic mice revealed endogenous circadian rhythms of P-gp protein expression with a shorter period, larger amplitude, and phase delay in females as compared to males. Importantly, this study provided model structure and parameter estimates to refine PK models of any P-gp substrate to account for sex, feeding and circadian rhythms.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Department of Pharmacology, Faculty of Pharmacy, Istanbul University, Beyazit, Istanbul, Turkey
2 Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry, UK
3 INSERM and Paris Sud university, UMRS 935, Team “Cancer Chronotherapy and Postoperative Liver Functions”, Campus CNRS, Villejuif, France
4 Università degli Studi G. d’Annunzio Chieti e Pescara, Institute for Advanced Biomedical Technologies, Chieti, Italy
5 Department of Biostatistics and Medical Informatics, Faculty of Medicine, Ege University, Bornova, Turkey
6 Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry, UK; INSERM and Paris Sud university, UMRS 935, Team “Cancer Chronotherapy and Postoperative Liver Functions”, Campus CNRS, Villejuif, France